Evaluation of tumor infiltrating lymphocytes (TIL) showed increased granzyme A+ CD8+ T cells, but no differences among effector CD4 T cells, supporting the hypothesis that pegzilarginase /aOX40 therapy augments CD8 T cell-mediated anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.